/

Società

Sp

Non verificato

SpliceBio

Di cosa scriviamo

BiologiaFarmaceuticaMedicina - VarieSaluteSanità

5 comunicati stampa

Guarda tutti i comunicati

08/01/2026

Biotecnologia

Igiene alimentare

Salute

Sanità

Farmaceutica

Ottica

Oncologia

Scienza

Medicina - Varie

Industria

SpliceBio Initiates Dose-Expansion Portion of Phase 1/2 ASTRA Clinical Trial for SB-007, a Dual-AAV Gene Therapy for Stargardt Disease

Fonte

Emittente

1.00

0

06/01/2026

SpliceBio Appoints Don Munoz as Chief Financial Officer

Fonte

Emittente

1.00

0

11/06/2025

Salute

Fitness

Economia

Medicina - Varie

Ecologia/Salute ambientale

Agricoltura

SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines

Fonte

Emittente

1.00

0

13/03/2025

Farmaceutica

Sanità

Biologia

SpliceBio Announces First Patient Dosed in Phase 1/2 ASTRA Study of SB-007, a Dual-AAV Gene Therapy for Stargardt Disease

Fonte

Emittente

1.00

0

12/12/2024

Farmaceutica

Sanità

Biologia

SpliceBio Announces U.S. FDA IND Clearance of SB-007 to Commence Phase 1/2 Clinical Study in Patients with Stargardt Disease

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0